NCT01067066 - A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 3, 2010

Primary Completion Date

July 6, 2016

Study Completion Date

July 6, 2016

Conditions

Melanoma

Interventions

DRUG

TPI 287

Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)

DRUG

Temodar (Temozolomide)

Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston